1. Home
  2. UNM vs UTHR Comparison

UNM vs UTHR Comparison

Compare UNM & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Unum Group

UNM

Unum Group

HOLD

Current Price

$74.37

Market Cap

12.4B

Sector

Finance

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$488.92

Market Cap

20.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UNM
UTHR
Founded
1848
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Accident &Health Insurance
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.4B
20.3B
IPO Year
1986
1999

Fundamental Metrics

Financial Performance
Metric
UNM
UTHR
Price
$74.37
$488.92
Analyst Decision
Buy
Buy
Analyst Count
12
12
Target Price
$94.67
$495.08
AVG Volume (30 Days)
1.2M
424.3K
Earning Date
11-03-2025
10-29-2025
Dividend Yield
2.48%
N/A
EPS Growth
N/A
16.08
EPS
5.18
26.38
Revenue
$13,068,000,000.00
$3,128,400,000.00
Revenue This Year
$3.55
$13.64
Revenue Next Year
$3.06
$5.78
P/E Ratio
$14.35
$18.55
Revenue Growth
2.13
13.50
52 Week Low
$66.81
$266.98
52 Week High
$84.48
$492.62

Technical Indicators

Market Signals
Indicator
UNM
UTHR
Relative Strength Index (RSI) 43.15 68.10
Support Level $73.03 $470.13
Resistance Level $77.30 $492.62
Average True Range (ATR) 1.32 10.72
MACD -0.31 -0.53
Stochastic Oscillator 26.60 89.55

Price Performance

Historical Comparison
UNM
UTHR

About UNM Unum Group

Unum Group is a provider of group and individual income protection insurance products in the United States, the United Kingdom, Poland, and other countries. It is the domestic disability insurer, with the majority of premiums generated from employer plans. The company also offers a complementary portfolio of other insurance products, including long-term care insurance, life insurance, and employer- and employee-paid group benefits. It has the following operating business segments: Unum USA, Unum International, Closed Block, Colonial Life, and Corporate. The majority of the revenue is earned from the Unum USA segment. The firm markets its products through brokers.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: